Literature DB >> 23306839

The fatty acid profile of the erythrocyte membrane in initial-onset inflammatory bowel disease patients.

Kan Uchiyama1, Shunichi Odahara, Makoto Nakamura, Shigeo Koido, Kiyohiko Katahira, Hiromi Shiraishi, Toshifumi Ohkusa, Kiyotaka Fujise, Hisao Tajiri.   

Abstract

BACKGROUND AND OBJECTIVES: The sudden change in the dietary habits of the Japanese population towards a European/American-style diet since the 1960s is thought to be responsible for the recent increase in the incidence of inflammatory bowel disease (IBD) in Japan. Dietary fatty acid intake influences the fatty acid profiles of vital cell membranes, which might be a source of inflammatory mediators.
METHODS: We investigated the fatty acid composition of the erythrocyte membrane in 90 healthy Japanese and 43 initial-onset IBD patients (ulcerative colitis, UC: 25; Crohn's disease, CD: 18) who had not undergone any dietary intervention to examine the role fatty acids play in the onset of IBD.
RESULTS: The erythrocyte membrane n-3/n-6 ratio of the initial-onset IBD patients was 0.42 ± 0.13, which was not significantly different from that of the healthy Japanese subjects (0.41 ± 0.13). However, the CD patients displayed a significantly lower mean percentage weight (MPW) of linoleic acid (LA) than the healthy subjects (8.25 ± 1.75 vs. 9.90 ± 1.29; p < 0.001), while their MPW of arachidonic acid (AA) was significantly higher than those of the healthy subjects and UC patients (11.22 ± 2.18 vs. 9.76 ± 1.64, p < 0.01; vs. 9.58 ± 1.97, p < 0.01, respectively). The mean delta 6-desaturation index of the CD patients was significantly higher than that of the healthy subjects (1.61 ± 0.65 vs. 1.11 ± 0.26; p < 0.001).
CONCLUSIONS: The CD patients displayed significantly higher and lower MPW of AA and LA, respectively, than the healthy subjects, suggesting that delta 6-desaturase is hyperactivated in CD. The cell membrane fatty acid profile might be a therapeutic target in CD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23306839     DOI: 10.1007/s10620-012-2508-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  25 in total

Review 1.  Epidemiology of inflammatory bowel disease in Asia.

Authors:  S K Yang; E V Loftus; W J Sandborn
Journal:  Inflamm Bowel Dis       Date:  2001-08       Impact factor: 5.325

2.  Clinical epidemiology of inflammatory bowel disease in Lebanon.

Authors:  Heitham Abdul-Baki; Ihab ElHajj; Lara M N El-Zahabi; Cecilio Azar; Elie Aoun; Hala Zantout; Walid Nasreddine; Bassem Ayyach; Fadi H Mourad; Assaad Soweid; Kassem A Barada; Ala I Sharara
Journal:  Inflamm Bowel Dis       Date:  2007-04       Impact factor: 5.325

Review 3.  New global map of Crohn's disease: Genetic, environmental, and socioeconomic correlations.

Authors:  Michael Economou; Georgios Pappas
Journal:  Inflamm Bowel Dis       Date:  2008-05       Impact factor: 5.325

4.  N-3 polyunsaturated fatty acid diet therapy for patients with inflammatory bowel disease.

Authors:  Kan Uchiyama; Makoto Nakamura; Shunichi Odahara; Shigeo Koido; Kiyohiko Katahira; Hiromi Shiraishi; Toshifumi Ohkusa; Kiyotaka Fujise; Hisao Tajiri
Journal:  Inflamm Bowel Dis       Date:  2010-10       Impact factor: 5.325

5.  Epidemiology of Crohn's disease in Israel: a survey of Israeli kibbutz settlements.

Authors:  Y Niv; G Abuksis; G M Fraser
Journal:  Am J Gastroenterol       Date:  1999-10       Impact factor: 10.864

6.  Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the aetiology of ulcerative colitis: a nested case-control study within a European prospective cohort study.

Authors:  A Tjonneland; K Overvad; M M Bergmann; G Nagel; J Linseisen; G Hallmans; R Palmqvist; H Sjodin; G Hagglund; G Berglund; S Lindgren; O Grip; D Palli; N E Day; K-T Khaw; S Bingham; E Riboli; H Kennedy; A Hart
Journal:  Gut       Date:  2009-07-23       Impact factor: 23.059

7.  Maintenance of lower proportions of (n - 6) eicosanoid precursors in phospholipids of human plasma in response to added dietary (n - 3) fatty acids.

Authors:  W E Lands; B Libelt; A Morris; N C Kramer; T E Prewitt; P Bowen; D Schmeisser; M H Davidson; J H Burns
Journal:  Biochim Biophys Acta       Date:  1992-12-10

8.  Fatty acid desaturase activities are modulated by phytosterol incorporation in microsomes.

Authors:  A I Leikin; R R Brenner
Journal:  Biochim Biophys Acta       Date:  1989-09-25

9.  Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.

Authors:  P A van Hees; J H Bakker; J H van Tongeren
Journal:  Gut       Date:  1980-07       Impact factor: 23.059

10.  Effects of highly purified eicosapentaenoic acid on erythrocyte fatty acid composition and leukocyte and colonic mucosa leukotriene B4 production in children with ulcerative colitis.

Authors:  Toshiaki Shimizu; Tohru Fujii; Ryuyo Suzuki; Jun Igarashi; Yoshikazu Ohtsuka; Satoru Nagata; Yuichiro Yamashiro
Journal:  J Pediatr Gastroenterol Nutr       Date:  2003-11       Impact factor: 2.839

View more
  3 in total

1.  Dyslipidemia and inflammation in patients with inflammatory bowel disease.

Authors:  Fatih Karaahmet; Omer Basar; Sahin Coban; Ilhami Yuksel
Journal:  Dig Dis Sci       Date:  2013-03-16       Impact factor: 3.199

2.  The risk of essential fatty acid insufficiency in patients with inflammatory bowel diseases: fatty acid profile of phospholipids in serum and in colon biopsy specimen.

Authors:  Jolanta Bugajska; Joanna Berska; Małgorzata Zwolińska-Wcisło; Krystyna Sztefko
Journal:  Arch Med Sci       Date:  2022-06-03       Impact factor: 3.707

3.  Untargeted Metabolomics of Extracts from Faecal Samples Demonstrates Distinct Differences between Paediatric Crohn's Disease Patients and Healthy Controls but No Significant Changes Resulting from Exclusive Enteral Nutrition Treatment.

Authors:  Adel Alghamdi; Konstantinos Gerasimidis; Gavin Blackburn; Didem Akinci; Christine Edwards; Richard K Russell; David G Watson
Journal:  Metabolites       Date:  2018-11-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.